Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PYXS
stocks logo

PYXS

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
--
--
-0.300
+400%
--
--
-0.297
+2.3%
--
--
-0.297
-15.24%
Estimates Revision
The market is revising No Change the revenue expectations for Pyxis Oncology, Inc. (PYXS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.00%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.19%
In Past 3 Month
Stock Price
Go Down
down Image
-10.00%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 7.25 USD with a low forecast of 5.00 USD and a high forecast of 10.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 1.170
sliders
Low
5.00
Averages
7.25
High
10.00
up Image0
Current: 1.170
sliders
Low
5.00
Averages
7.25
High
10.00
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$5
2025-03-19
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$5
2025-03-19
Reiterates
Strong Buy
Reason
RBC Capital
Leonid Timashev
Buy
Reiterates
$8
2025-03-19
Reason
RBC Capital
Leonid Timashev
Price Target
$8
2025-03-19
Reiterates
Buy
Reason
RBC Capital
Leonid Timashev
Buy
Reiterates
$10 → $8
2024-12-20
Reason
RBC Capital
Leonid Timashev
Price Target
$10 → $8
2024-12-20
Reiterates
Buy
Reason
RBC Capital analyst Leonid Timashev lowered the firm's price target on Pyxis Oncology to $8 from $10 and keeps an Outperform rating on the shares. The company's pipeline update to prioritize PYX-201 over further investment in PYX-106 is "prudent" given the early signs of activity and the operating expense savings that will be leveraged to continue to advance PYX-201 development, though the firm is reducing its price target on lower "pipeline optionality", the analyst tells investors in a research note.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$7 → $5
2024-12-20
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$7 → $5
2024-12-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$7
2024-11-21
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$7
2024-11-21
Reiterates
Strong Buy
Reason
William Blair
Andy Hsieh
Buy
to
Hold
Downgrades
n/a
2024-11-21
Reason
William Blair
Andy Hsieh
Price Target
n/a
2024-11-21
Downgrades
Buy
to
Hold
Reason
William Blair analyst Andy Hsieh downgraded Pyxis Oncology to Market Perform from Outperform.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pyxis Oncology Inc (PYXS.O) is -0.84, compared to its 5-year average forward P/E of -1.96. For a more detailed relative valuation and DCF analysis to assess Pyxis Oncology Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.96
Current PE
-0.84
Overvalued PE
-0.33
Undervalued PE
-3.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.20
Current EV/EBITDA
0.30
Overvalued EV/EBITDA
1.51
Undervalued EV/EBITDA
-1.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
78.27
Current PS
0.00
Overvalued PS
238.71
Undervalued PS
-82.17

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

PYXS News & Events

Events Timeline

(ET)
2025-03-18
07:32:31
Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)
select
2025-02-26 (ET)
2025-02-26
07:34:31
Pyxis Oncology granted Fast Track designation for PYX-201 monotherapy
select
2024-12-19 (ET)
2024-12-19
15:17:10
Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106
select
Sign Up For More Events
Sign Up For More Events

News

Preview
1.0
04-02Newsfilter
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

  • Company Announcement: Pyxis Oncology, Inc. will have its CEO, Dr. Lara S. Sullivan, participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on April 9, 2025, and will also conduct one-on-one investor meetings during the event.

  • Product Development Focus: The company is advancing its lead product candidate, MICVO, an antibody-drug conjugate targeting difficult-to-treat cancers, particularly focusing on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Preview
9.0
03-26Newsfilter
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

  • Preclinical Data Presentation: Pyxis Oncology is set to present promising preclinical data on micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting EDB+FN, at the AACR Annual Meeting, highlighting its potential efficacy in treating recurrent and metastatic head and neck squamous cell carcinoma.

  • Clinical Trials Advancement: The company is advancing MICVO into clinical trials as both a monotherapy and in combination with Merck's Keytruda, with preliminary data expected in late 2025 and early 2026, following positive results from earlier studies indicating significant tumor regression.

Preview
4.0
03-20Business Insider
RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

  • Analyst Ratings: RBC Capital's Leonid Timashev maintains a Buy rating on Pyxis Oncology with a price target of $8.00, while LifeSci Capital also issued a Buy rating; however, William Blair reiterated a Hold rating.

  • Stock Performance: Pyxis Oncology's shares closed at $1.07, with a one-year high of $6.18 and a low of $0.99, indicating significant volatility in its stock performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pyxis Oncology Inc (PYXS) stock price today?

The current price of PYXS is 1.17 USD — it has increased 1.74 % in the last trading day.

arrow icon

What is Pyxis Oncology Inc (PYXS)'s business?

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

arrow icon

What is the price predicton of PYXS Stock?

Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 7.25 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pyxis Oncology Inc (PYXS)'s revenue for the last quarter?

Pyxis Oncology Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Pyxis Oncology Inc (PYXS)'s earnings per share (EPS) for the last quarter?

Pyxis Oncology Inc. EPS for the last quarter amounts to -0.58 USD, increased 65.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pyxis Oncology Inc (PYXS)'s fundamentals?

The market is revising No Change the revenue expectations for Pyxis Oncology, Inc. (PYXS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.00%.
arrow icon

How many employees does Pyxis Oncology Inc (PYXS). have?

Pyxis Oncology Inc (PYXS) has 50 emplpoyees as of May 14 2025.

arrow icon

What is Pyxis Oncology Inc (PYXS) market cap?

Today PYXS has the market capitalization of 71.24M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free